Clinical Trials Logo

Filter by:
NCT ID: NCT01522807 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study Of Three PF-05190457 Formulations In Healthy Volunteers

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the plasma drug concentrations of three formulations of PF-05190457 after administration of single doses to healthy volunteers.

NCT ID: NCT01521767 Completed - Clinical trials for Urinary Bladder, Overactive

Pharmacokinetics and Relative Bioavailability Study

Start date: October 2011
Phase: Phase 1
Study type: Interventional

A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules

NCT ID: NCT01515358 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants

Start date: February 2012
Phase: Phase 1
Study type: Interventional

The purposes of this study are to determine the safety and side effects of LY3000328, to determine how well the body will tolerate LY3000328, and to determine how long LY3000328 remains in the body.

NCT ID: NCT01513928 Completed - Healthy Clinical Trials

A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects

Start date: January 2012
Phase: Phase 1
Study type: Interventional

This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319

NCT ID: NCT01512758 Completed - Clinical trials for Advanced Solid Tumors

A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas

Start date: February 6, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of alisertib twice daily (BID) dosing for 7 days in East Asian participants with advanced solid tumors or lymphomas. The secondary objective was to describe any antitumor activity that may have been observed with alisertib treatment.

NCT ID: NCT01511250 Completed - Healthy Clinical Trials

Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years

Start date: November 16, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children. In addition the antibody response to the four dengue virus serotypes will be evaluated.

NCT ID: NCT01507168 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Start date: February 2, 2012
Phase: Phase 2
Study type: Interventional

This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety of GC33 (RO5137382) in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma. Participants will be stratified according to the level of GPC-3 expression in tumors and randomized to receive either GC33 (1600 mg intravenously) or placebo on Days 1 and 8 of Cycle 1 and every 2 weeks thereafter. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

NCT ID: NCT01506856 Completed - Clinical trials for Fallopian Tube Cancer

Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial

iPocc
Start date: May 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is: Phase A: To confirm the feasibility of paclitaxel administered by intravenous (IV) infusion weekly plus concurrent carboplatin administered by intraperitoneal (IP) injection once every 3 weeks (dd-TCip therapy). Phase B: To compare the efficacy and safety of the following two treatment regimens as first-line chemotherapy in women with epithelial ovarian, Fallopian tube or primary peritoneal cancer.

NCT ID: NCT01499004 Completed - Healthy Clinical Trials

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Start date: November 2011
Phase: Phase 1
Study type: Interventional

This study will explore the drug behavior and safety following a single dose of three different 22 milligram tofacitinib (CP-690,550) modified-release formulations in 30 healthy volunteers. These formulations will be compared to 10 milligram tofacitinib (CP-690-550) in an immediate-release formulation.

NCT ID: NCT01494181 Completed - Clinical trials for Obstructive Sleep Apnea

Unrecognised Obstructive Sleep Apnea Study

OSA
Start date: July 2011
Phase: N/A
Study type: Observational

Plan of investigation: This is an observational cohort study to determine the effect of OSA, independent of other risk factors, on postoperative vascular events. The study is conceived, designed and will be conducted, and analyzed independent to any company. There is no commercial sponsorship.